Acute Coronary Syndrome (ACS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Acute Coronary Syndrome (ACS) covers a range of coronary artery diseases, including unstable angina, ST-elevation myocardial infarction (STEMI), and non-ST elevation myocardial infarction (non-STEMI). The primary challenge in diagnosis lies in distinguishing ACS from noncardiac chest pain. Symptoms of ACS encompass chest pain, referred pain, nausea, vomiting, dyspnea, diaphoresis, and lightheadedness. According to a study, sudden dyspnea alone was the presenting symptom in 4 to 14 percent of acute myocardial infarction cases. Pain can be referred to the arm, jaw, neck, back, or abdomen. ACS is more likely if the pain radiates to the shoulder, left arm, or both arms. Typical angina is characterized by substernal pain during exertion, alleviated by rest. Patients displaying all three characteristics are more likely to have ACS than those with fewer. Chest pain emerging suddenly at rest or in young patients may indicate Prinzmetal’s angina or acute coronary vasospasm, often associated with cocaine or methamphetamine use. ACS accounts for only about 2% of cases of cocaine-related chest pain. The FDA has approved several drugs for ACS, including Brilinta (ticagrelor), Plavix (clopidogrel bisulfate), Effient (prasugrel), and Praluent (alirocumab).
• In the USA, the incidence of ACS ranges from 0.9% to 1.5%.

Thelansis’s “Acute Coronary Syndrome (ACS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Coronary Syndrome (ACS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Acute Coronary Syndrome (ACS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Acute Coronary Syndrome (ACS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Acute Coronary Syndrome (ACS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033